Oral Tofacitinib for the Management of Moderate to Severe Alopecia Areata in Children and Adolescents: A Retrospective Study of 36 Patients

This retrospective study evaluated the efficacy and safety of oral tofacitinib in 36 children and adolescents with moderate to severe alopecia areata (AA). The study found that 72.2% of patients achieved a SALT75 score, indicating significant hair regrowth, and 52.8% achieved a SALT100 score, indicating complete regrowth, within an average of 4.1 and 6.7 months, respectively. However, 27.8% of patients did not respond to the treatment. Nine patients experienced adverse events, with two discontinuing treatment due to these events. The study concludes that tofacitinib is effective for pediatric AA, but further research is needed to understand the long-term benefits and maintenance therapy requirements.